Dupilumab Reduces COPD Exacerbations for Patient with T2 Inflammation in Landmark Phase 3 Trial
Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.
